Journal Information
Vol. 5. Issue 2.
Pages 49-54 (March - April 2009)
Share
Share
Download PDF
More article options
Vol. 5. Issue 2.
Pages 49-54 (March - April 2009)
Full text access
A study on the subjective compliance and acceptance of oral lanzoprazole in traumatology. The ECOFT-TR Study
Estudio sobre el cumplimiento subjetivo y la aceptabilidad de lansoprazol comprimidos bucodipersables en traumatología. Estudio ECOF-TR
Visits
4900
Emilio Márquez-Contrerasa,
Corresponding author
emarquezc@papps.org

Corresponding author.
, Vicente Gil-Guillénb, Albert Nadal-Sánchezc, M. José Plazas-Fernándezd, Joan Heras-Navarrod, Jordi Galván-Cerverad, Joana Porcel-Carbonelle
a La Orden Health Center, Huelva, Spain
b Monovar Health Center, Alicante, Spain
c Teknon Medical Center, Barcelona, Spain
d Almirall Laboratories, S.A., Barcelona, Spain
e Clinical Biometrics S.L. Barcelona, Spain
This item has received
Article information
Abstract
Objective

To assess compliance with oral lansoprazolee disintegrating tablets (LODT) in patients treated by traumatology specialists.

Material and method

A multicenter, observational, cross-sectional study involving 370 traumatology specialists and patients aged 18 or more. Study logistics were sponsored by Almirall Laboratories, S.A.; neither investigators nor patients received any economic compensation for their participation. Patient subjective compliance with LODT was assessed with the Haynes Sackett test. Acceptability was based on patients global assessments of the drug organoleptic characteristics and properties of use, and preferences regarding previous treatments, recorded by means of a self-administered 15-item ad hoc questionnaire with a 2–5-point Likert-type scale, that patients fulfilled once.

Results

One thousand and eighty five patients were analyzed for the main endpoint. Mean age was 56.09 (13.8) years; 56.77% were women. Mean treatment duration was 51.24 (38.8) days. 94.74% of the patients complied with the treatment. Mean percentage of compliance was 94.5 (12.12); 91.09% of patients rated the treatment as “acceptable or highly acceptable.” No significant differences were observed between compliant and non-compliant patients in terms of demographic or clinical variables. Mean percentage of compliance was significantly higher among patients without concomitant illness or treatment and without difficulties in taking tablets. One non-serious adverse reaction was reported in one (0.09%) patient.

Conclusions

Compliance with lansoprazolee orally disintegrating tablets was high. Patients reported that this formulation improved their compliance and that they preferred LODT to previous medication. Tolerability was excellent.

Keywords:
Lansoprazolee
Orally disintegrating tablets
Acceptability
Subjetive compliance
Resumen
Objetivo

Valorar el cumplimiento terapéutico con lansoprazol, comprimidos bucodispersables, en pacientes tratados por especialistas en traumatología.

Material y método

Estudio observacional, transversal. Participaron 370 especialistas en traumatología que incluyeron a pacientes con un mínimo de 18 años. Los aspectos logísticos del estudio fueron financiados por Laboratorios Almirall, S.A.; los investigadores y pacientes no percibieron compensación alguna por su participación en el estudio. La valoración subjetiva del cumplimiento con lansoprazol comprimidos bucodispersables se realizó mediante el test de Haynes-Sackett. La aceptabilidad del tratamiento, considerada como la valoración general del paciente tras evaluar las características organolépticas y propiedades de uso, y su preferencia con respecto a tratamientos previos, se evaluó mediante un cuestionario ad hoc, autoaplicado, de 15 ítems con una escala tipo Likert con 2–5 posibles respuestas, que los pacientes cumplimentaron en una única ocasión.

Resultados

Fueron valorables 1.085 pacientes, con una media±desviación estándar de edad de 56,09±13,8 años; un 56,77% eran mujeres. La media de tiempo en tratamiento fue 51,24±38,8 días. El 94,74% de los pacientes cumplieron con el tratamiento. El grado medio de cumplimiento fue 94,5±12,12. El 91,09% de los pacientes calificó el tratamiento como «muy aceptable/aceptable». No hubo diferencias significativas en el porcentaje de pacientes cumplidores según las variables demográficas y clínicas. El grado o porcentaje de cumplimiento fue significativamente mejor entre los pacientes sin enfermedades y tratamientos concomitantes y sin dificultad en la toma de comprimidos. Para 1 (0,09%) paciente se notificó una reacción adversa no grave.

Conclusiones

El cumplimiento con lansoprazol comprimidos bucodispersables fue muy elevado. Los pacientes valoraron que la formulación bucodispersable de lansoprazol les ayudaba a cumplir mejor con el tratamiento y lo prefirieron al que recibían previamente. La tolerabilidad fue excelente.

Palabras clave:
Lansoprazol
Comprimidos bucodispersables
Cumplimiento subjetivo
Aceptabilidad
Full text is only aviable in PDF
References
[1.]
Catálogo de especialidades, farmacéuticas. Consejo General de Colegios Oficiales de Farmacéuticos; 2000.
[2.]
F. Baldi, P. Malfertheiner.
Lansoprazole fast disgregating tablet: a new formulation for an established proton pump inhibitor.
Digestion, 67 (2003), pp. 1-5
[3.]
N.M. Agrawal, D.R. Campbell, M.A. Safdi, N.L. Lukasik, B. Huang, M.M. Haber.
Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group.
Arch Intern Med, 160 (2000), pp. 1455-1461
[4.]
E. Márquez, J.J. Casado, J.J. Márquez.
Estrategias para mejorar el cumplimiento.
FMC, 8 (2001), pp. 558-573
[5.]
S. Jay, I.F. Litt, R.H. Durant.
Compliance with therapeutic regimens.
J Adolesc Health Care, 5 (1984), pp. 124-136
[6.]
R.L. Bown.
An overview of the pharmacology, efficacy, safety and costeffectiveness of lansoprazole.
Int J Clin Pract, 56 (2002), pp. 132-139
[7.]
O. Andersen, O.K. Zweidorff, T. Hjelde, E.A. Rodland.
Problems when swallowing tablets. A questionnaire study from general practice.
Tidsskr Nor Laegeforen, 115 (1995), pp. 947-949
[8.]
H. Seager.
Drug-delivery products and the Zydis fast-dissolving dosage form.
J Pharm Pharmacol, 50 (1998), pp. 375-382
[9.]
P. D’Eliseo, J. Blaauw, Z. Milicevic, J. Wyatt, D.A. Ignaut, J.K. Malone.
Patient acceptability of a new 3.0ml pre-filled insulin pen.
Curr Med Res Opin, 16 (2000), pp. 125-133
[10.]
T.P. Rees, I. Howe.
A randomised, single-blind, crossover comparison of the acceptability of the calcium and vitamin D3 supplements Calcichew D3 Forte and Ad Cal D3 in elderly patients.
Curr Med Res Opin, 16 (2001), pp. 245-251
[11.]
R.A. Gerber, J.C. Cappelleri, I.A. Kourides, R.A. Gelfand.
Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial.
Diabetes Care, 24 (2001), pp. 1556-1559
[12.]
S. Ristic, P.C. Bates, J.M. Martin, J.A. Llewelyn.
Acceptability of a reusable insulin pen, HumaPen Ergo, by patients with type 1 and type 2 diabetes.
Curr Med Res Opin, 18 (2002), pp. 68-71
[13.]
M.R. Kaplan, C.L. Stashenko, A.L. Bledsoe, J. McGowan.
A preference study: calcium acetate tablets versus gelcaps in hemodialysis patients.
Nephrol Nurs J, 29 (2002), pp. 363-365
[14.]
A. Roger, M.J. Plazas, J. Galván, J. Heras, M. Artés, E. Gabarrón.
Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectancies.
Allergol Immunopathol, 34 (2006), pp. 107-112
[15.]
I.B. McIntosh.
Butazolidin suppository medication in rheumatism; a clinical study in general practice.
J Int Med Res, 5 (1977), pp. 81-84
[16.]
A. Andren-Sandberg.
Theory and practice in the individualization of oral pancreatic enzyme administration for chronic pancreatitis.
Int J Pancreatol, 5 (1989), pp. 51-62
[17.]
H. Barnebey, S.Y. Kwok.
Patients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting.
Clin Ther, 22 (2000), pp. 1204-1212
[18.]
S.P. Roose.
Compliance: the impact of adverse events and tolerability on the physician's treatment decisions.
Eur Neuropsychopharmacol, 13 (2003), pp. S85-S92
[19.]
J.W. Freston, Y.L. Chiu, D.J. Mulford, E.D. Ballard.
Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects.
Aliment Pharmacol Ther, 17 (2003), pp. 361-367
[20.]
Hintze J. NCSS and PASS. Number Cruncher Statistical Systems. Kaysvill, Utah; 2001. Available from: www.ncss.com.
[21.]
D.L. Sackett, J.C. Snow.
The magnitude of compliance and noncompliance.
Johns Hopkins, (1979),
[22.]
R.B. Haynes, D.W. Taylor, D.L. Sackett, E.S. Gibson, C.D. Bernholz, J. Mukherjee.
Can simple clinical measurements detect patient noncompliance?.
Hypertension, 2 (1980), pp. 757-764
[23.]
C.M. de Argila, J. Ponce, E. Márquez, M.J. Plazas, J. Galván, J. Heras, et al.
Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease: ACEPTO study.
Clin Drug Investig, 27 (2007), pp. 765-770
[24.]
E. Márquez-Contreras, V. Gil, J. López, M.J. Plazas, J. Heras, J. Galván, et al.
Pharmacological compliance and acceptability of lansoprazolee orally disintegrating tablets in primary care.
Curr Med Res Opin, 24 (2008), pp. 569-576
[25.]
Y. Lake, S. Pinnock.
Improved patient acceptability with a transdermal drug-inadhesive oestradiol patch.
Aust N Z J Obstet Gynaecol, 40 (2000), pp. 313-316
Copyright © 2009. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?